Car T Cell Therapy Aml

However progress has been made toward the use of car t cell therapy in this disease prompting the topic of this paper.

Car t cell therapy aml. The t cells from patients or transplantation donors will be genetically modified with lentiviral car vector to recognize specific molecules cd33 cd123 or cll 1 expressed on the surface of aml cells. The engineered t cells will be applied to patients through intravenous delivery. However progress has been made toward the use of car t cell therapy in this disease prompting the topic of this paper. However these same antigens are also shared by healthy hspcs and their myeloid and or lymphoid progenitors 24.

Novel treatment options such as chimeric antigen receptor car t cells are needed for patients with this disease. The purpose of this clinical trial is to assess the feasibility safety and efficacy of multiple car t cell therapy in aml. The success of anti cd19 car t cell therapy in relapsed pediatric b lineage acute lymphoblastic leukemia b all has so far not been translated into treatment for acute myeloid leukemia aml. Therapies for acute myeloid leukemia aml have not improved patient long term survival for decades.

Aml cells express various cell surface antigens including cd123 cd34 cd33 and many others. The fundamental biological barrier limiting the application of car t cell therapy in aml is the absence of an aml specific antigen. This might be due to a lack of unique antigens on the surface of aml cells that would allow selective targeting of these cells while sparing healthy hematopoietic stem progenitor cells hspc. A similar approach for myeloid malignancies is highly desirable.

Chimeric antigen receptor car t cell therapy for acute myeloid leukemia aml has thus far been elusive in part owing to the absence of truly aml specific surface antigens making aml difficult to target. The t cells are then genetically modified in a laboratory to produce car. Chimeric antigen receptor car t cell therapy helps the immune system to fight cancer cells. In this treatment immune cells the t cells are removed from the blood.

Chimeric antigen receptor car t cell therapy for acute myeloid leukemia aml has thus far been elusive in part owing to the absence of truly aml specific surface antigens making aml difficult to target. It is the proof of concept for t cell based immunotherapies in aml based on the graft versus leukemia gvl effect but it also bears the risk of graft versus host disease. However aml cells lack ideal targeting antigens that are safe to target with car t cells.